Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Muzastotug by Adagene Suzhou for Non-Small Cell Lung Cancer: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Non-Small Cell Lung Cancer. According to...
ADG-106 by Adagene Suzhou for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
ADG-106 is under clinical development by Adagene Suzhou and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Muzastotug by Adagene Suzhou for Endometrial Cancer: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
Muzastotug by Adagene Suzhou for Cervical Cancer: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...
Muzastotug by Adagene Suzhou for Metastatic Colorectal Cancer: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
Muzastotug by Adagene Suzhou for Anal Cancer: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Anal Cancer. According to GlobalData, Phase...
Muzastotug by Adagene Suzhou for Penile Cancer: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Penile Cancer. According to GlobalData, Phase...
ADG-116 by Adagene Suzhou for Colorectal Cancer: Likelihood of Approval
ADG-116 is under clinical development by Adagene Suzhou and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...
ADG-116 by Adagene Suzhou for Endometrial Cancer: Likelihood of Approval
ADG-116 is under clinical development by Adagene Suzhou and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
ADG-116 by Adagene Suzhou for Kaposi Sarcoma: Likelihood of Approval
ADG-116 is under clinical development by Adagene Suzhou and currently in Phase II for Kaposi Sarcoma. According to GlobalData, Phase...
ADG-116 by Adagene Suzhou for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
ADG-116 is under clinical development by Adagene Suzhou and currently in Phase II for Head And Neck Squamous Cell Carcinoma...